I think Jon / NEU are approaching their FDA discussions regarding their proposed PMS Ph3 PMS trial in a very strategic manner.
Jon / NEU knows that obtaining a favourable / reduced set of requirements for the safety protocol and a clear set of requirements and end points similar to their Ph2 trial, will set the ground work for all future FDA discussions regarding new potential 2591 indications - including those discussions that Acadia may have with the FDA regarding 2591 for Rhett and Fragile X syndromes.
Despite the disappointment in the delay, I suspect Jon is very busy and focused on delivering more long-term value for shareholders that will enable this important new drug to be brought to the market to help many people sooner.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.55 |
Change
0.540(3.17%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.48 | $18.44 | $17.40 | $16.43M | 922.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2624 | $17.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.70 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |